Israel’s OCS Awards $1.1 Million To BrainStorm Cell Therapeutics For Amyotrophic Lateral Sclerosis
BrainStorm Cell Therapeutics Inc. received nearly $1.1 million in funding from Israel’s Office of the Chief Scientist (OCS) to support the development of NurOwn™, BrainStorm’s therapeutic platform for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). BrainStorm is a biotechnology company dedicated to the development of innovative adult…